Our conclusion that miR-301a promotes pancreatic cancer progression is also supported by previous reports, which have demonstrated this role through different pathways.26,27 Targeting miR-301a directly or modulating its interaction with Gli1 and STK4 offers a promising strategy to disrupt the pathological signaling driving PDAC. Here, STK4 is linked to pancreatic neoplasm.